SELLAS Life Sciences Group, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
SELLAS Life Sciences Group, Inc. (SLS) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$9.57 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-19
- SELLAS Life Sciences Group, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$9.57M.
- SELLAS Life Sciences Group, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$9.54M.
- SELLAS Life Sciences Group, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$10.12M.
- SELLAS Life Sciences Group, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$17.82M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$9.57M 10-K · filed 2026-03-19 |
| 2024-12-31 | -$9.54M 10-K · filed 2026-03-19 |
| 2023-12-31 | -$10.12M 10-K · filed 2025-03-20 |
| 2022-12-31 | -$17.82M 10-K · filed 2024-03-28 |
| 2021-12-31 | -$6.96M 10-K · filed 2023-03-16 |
| 2020-12-31 | -$4.66M 10-K · filed 2022-03-31 |
| 2019-12-31 | -$8.48M 10-K · filed 2021-03-23 |
| 2018-12-31 | -$17.18M 10-K · filed 2020-03-13 |
| 2017-12-31 | $265.00K 10-K · filed 2019-03-22 |
| 2016-12-31 | $108.00K 10-K · filed 2018-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |